NCT00254462 - Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2005

Primary Completion Date

August 1, 2008

Study Completion Date

September 1, 2008

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

Atomoxetine

Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.

DRUG

Placebo

Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.

BEHAVIORAL

Parent Training

All children will receive parent training for the duration of the study.

Trial Locations (3)

New York State Psychiatric Institute, New York

Duke University Medical Center, Durham

University of Nebraska Medical Center, Omaha

All Listed Sponsors

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Nebraska

OTHER